ArticleFrontiers in medicine2026
The clinical value of metabolic indicators in immunoglobulin A nephropathy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is a leading cause of end-stage renal disease (ESRD). There is a critical need for sensitive biomarkers to predict disease progression, as traditional indicators like serum creatinine (Scr) have limitations. This study investigates the association of routine metabolic indicators with renal function, pathology, and hospitalization expenses in IgAN patients. In this cross-sectional study, lactate dehydrogenase (LDH) levels were significantly correlated with mesangial hypercellularity (M) and tubular atrophy/interstitial fibrosis (T) in the MEST-C score in the Oxford classification. Furthermore, LDH levels showed a consistent association with estimated glomerular filtration rate (eGFR) and total hospitalization expenses in unadjusted and multivariable-adjusted analyses. Serum uric acid (SUA) levels also demonstrated a strong relationship with renal function. In lipid metabolism, high-density lipoprotein cholesterol was significantly associated with eGFR after multivariable adjustment, whereas triglycerides (TGs) showed correlations with eGFR only in the unadjusted analysis. Serum total protein (TP) levels exhibited a linear positive correlation with eGFR in the unadjusted analysis and emerged as a robust predictor of M, segmental glomerulosclerosis (S), and T lesions in the Oxford Classification. After false discovery rate correction for multiple comparisons, TP was found to be significantly associated with T lesions, which was the most crucial finding of our study, whereas associations involving LDH and other markers were exploratory. Importantly, S and T lesions were strongly associated with a decline in renal function and M1 lesions were found to respond favorably to corticosteroid therapy, whereas T2 lesions signaled an increased risk of progression to ESRD. These hypothesis-generating findings suggest that the strict control of lipid and SUA levels is essential for patients with IgAN in clinical practice. Elevated LDH and decreased TP levels may alert clinicians to the risks of renal function deterioration and ESRD. Moreover, such patients may respond favorably to corticosteroid therapy, which should be considered within the framework of KDIGO 2025 guidelines based on comprehensive risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.